China’s Nanjing TransThera Sciences (Nanjing), Inc. has announced the completion of a Series D+ financing round, raising RMB 260 million (USD 37.7 million). This follows the USD 100 million Series D funding secured in July 2021. The latest round was led by Guoxin Investment, with contributions from Trinity Innovation Fund, Wuxi Golden Control Qiyuan Investment, Nanjing Jiangbei New Area State-owned Assets Management, BOC Capital, Nanjing Baiyide Equity Investment, Wuxi Ruitong Venture Capital, and Honest Capital.
Company Overview and Pipeline
Founded in 2014, TransThera Biosciences is a clinical-stage company focused on the discovery and development of small molecule therapies targeting tumors, inflammation, and cardiovascular diseases. The company’s core product, tinengotinib, an FGFR inhibitor, is currently at the Phase II clinical stage. This product represents a significant advancement in the treatment of these conditions, offering a targeted approach to therapy.
Strategic Implications
The completion of the Series D+ financing round is a strategic milestone for TransThera Biosciences. The funds will be used to accelerate the development of tinengotinib and other pipeline products, enhancing the company’s position in the global biopharmaceutical market. By securing significant investment, TransThera is well-positioned to bring innovative therapies to patients in need, addressing significant unmet medical needs in the treatment of tumors, inflammation, and cardiovascular diseases.-Fineline Info & Tech
